- Home
- PAYS vs CTNM Comparison
PAYS vs CTNM Comparison
Compare PAYS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- CTNM
- Stock Information
- Founded
- PAYS 2001
- CTNM 2009
- Country
- PAYS United States
- CTNM United States
- Employees
- PAYS N/A
- CTNM N/A
- Industry
- PAYS Business Services
- CTNM
- Sector
- PAYS Consumer Discretionary
- CTNM
- Exchange
- PAYS Nasdaq
- CTNM Nasdaq
- Market Cap
- PAYS 125.2M
- CTNM 122.9M
- IPO Year
- PAYS 1998
- CTNM 2024
- Fundamental
- Price
- PAYS $7.65
- CTNM $3.77
- Analyst Decision
- PAYS Strong Buy
- CTNM Strong Buy
- Analyst Count
- PAYS 4
- CTNM 4
- Target Price
- PAYS $7.06
- CTNM $22.50
- AVG Volume (30 Days)
- PAYS 1.1M
- CTNM 221.9K
- Earning Date
- PAYS 08-05-2025
- CTNM 08-12-2025
- Dividend Yield
- PAYS N/A
- CTNM N/A
- EPS Growth
- PAYS N/A
- CTNM N/A
- EPS
- PAYS 0.11
- CTNM N/A
- Revenue
- PAYS $63,792,627.00
- CTNM N/A
- Revenue This Year
- PAYS $30.03
- CTNM N/A
- Revenue Next Year
- PAYS $20.14
- CTNM N/A
- P/E Ratio
- PAYS $69.92
- CTNM N/A
- Revenue Growth
- PAYS 26.77
- CTNM N/A
- 52 Week Low
- PAYS $1.80
- CTNM $3.35
- 52 Week High
- PAYS $8.57
- CTNM $21.92
- Technical
- Relative Strength Index (RSI)
- PAYS 67.31
- CTNM N/A
- Support Level
- PAYS $7.48
- CTNM N/A
- Resistance Level
- PAYS $8.57
- CTNM N/A
- Average True Range (ATR)
- PAYS 0.52
- CTNM 0.00
- MACD
- PAYS -0.06
- CTNM 0.00
- Stochastic Oscillator
- PAYS 58.93
- CTNM 0.00
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.